Asthma drug study pulled before it began
NCT ID NCT04973345
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to understand how the asthma drug terbutaline sulfate works in the body when given through a vein versus under the skin. Researchers planned to enroll adults with asthma to find the best dose. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- terbutaline sulfate
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data was collected. It is unclear if the approach would have been safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Vermont
Burlington, Vermont, 05401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI and a smartphone app may let kids with asthma skip clinic visits
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests
- Short steroid course after first wheeze may stop asthma before it starts
- New antibody drug aims to tame Hard-to-Control asthma
- New asthma drug aims to improve breathing without daily pills
- Scientists compare two formulations of a potential asthma treatment